# MT2015-20: Biochemical Correction of Severe EB by Allo HSCT and Serial Donor MSCs

> **NCT02582775** · PHASE2 · COMPLETED · sponsor: **Masonic Cancer Center, University of Minnesota** · enrollment: 17 (actual)

## Conditions studied

- Epidermolysis Bullosa

## Interventions

- **DRUG:** Thymoglobulin
- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine
- **RADIATION:** Total Body Irradiation
- **PROCEDURE:** Bone marrow infusion
- **DRUG:** Tacrolimus
- **DRUG:** Mycophenolate Mofetil
- **BIOLOGICAL:** Donor mesenchymal stem cell infusions
- **DRUG:** Busulfan

## Key facts

- **NCT ID:** NCT02582775
- **Lead sponsor:** Masonic Cancer Center, University of Minnesota
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03
- **Primary completion:** 2022-11-15
- **Final completion:** 2023-07-26
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02582775

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02582775, "MT2015-20: Biochemical Correction of Severe EB by Allo HSCT and Serial Donor MSCs". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT02582775. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*